Global MRNA Therapeutics Market: By Product Type, By Application, By End User, Hospitals & Clinics) and Region Forecast 2020-2031
MRNA Therapeutics Market size was valued at US$ 13,874.3 million in 2024 and is projected to reach US$ 40,898.5 million by 2031 at a CAGR of 16.7% from 2025-2031. The market refers to the global industry focused on the development, manufacturing, and commercialization of messenger RNA-based therapies. These therapies use synthetic mRNA to instruct cells to produce specific proteins that can help prevent or treat various diseases, including infectious diseases, cancers, and genetic disorders. Unlike traditional drugs, mRNA therapeutics work at the genetic level, offering a platform that is both versatile and rapidly adaptable, especially during outbreaks and emerging health threats.
The market has gained significant momentum in recent years, driven by the success of mRNA-based COVID-19 vaccines and growing investment in genetic medicine. Key players are actively expanding their pipelines to target a broader range of diseases, including rare disorders and chronic conditions. Technological advancements in lipid nanoparticle delivery systems, improved stability of mRNA molecules, and favourable regulatory support are further accelerating market growth. As a result, the market is poised for continued expansion, with strong interest from both pharmaceutical companies and investors seeking scalable and personalized treatment options.
Based on the product type
Based on product type, mRNA vaccines are anticipated to lead the market growth in the coming years. This dominance is primarily driven by the widespread adoption and success of mRNA-based COVID-19 vaccines, which have demonstrated the technology’s effectiveness and rapid development capabilities. The ability of mRNA vaccines to be quickly designed and produced against emerging infectious diseases has attracted significant investment and regulatory support globally. Additionally, ongoing research is expanding mRNA vaccines to target other infectious diseases like influenza and Zika, further strengthening their position as the leading product segment within the market.
Based on the application
Based on application, the Infectious Diseases segment is expected to lead the market. This dominance is largely due to the successful deployment of mRNA vaccines during the COVID-19 pandemic, which showcased the technology’s ability to rapidly respond to global health emergencies. The effectiveness and scalability of mRNA-based vaccines against infectious agents have driven substantial investment and accelerated development pipelines targeting other infectious diseases such as influenza, Zika, and respiratory syncytial virus (RSV). Continued innovation and government support in this area are anticipated to maintain infectious diseases as the leading application segment in the market.
Based on the end user
Based on end user, Pharmaceutical & Biotechnology Companies are projected to lead the market. These companies play a pivotal role in driving market growth through extensive investments in research, development, and commercialization of mRNA-based products. The success of mRNA vaccines during the COVID-19 pandemic has encouraged these organizations to expand their pipelines, focusing on both vaccines and therapeutic applications. Their ability to scale manufacturing, navigate regulatory pathways, and form strategic partnerships positions them at the forefront of market advancement. Consequently, pharmaceutical and biotech firms remain the primary drivers shaping the future of the mRNA therapeutics landscape.
Study Period
2025-2031Base Year
2024CAGR
16.7%Largest Market
Asia-PacificFastest Growing Market
North-America
One of the drivers of the market is the record speed and flexibility of mRNA technology. In contrast to conventional drug development that usually takes years, mRNA therapeutics take only weeks to be designed and manufactured, as seen in the rapid development of COVID-19 vaccines. This pace is because of the platform-based character of mRNA, wherein only the target antigen sequence has to be modified and the production and delivery systems have to be the same. This allows for swift response to outbreak diseases, mutations, or even individualized treatment requirements, particularly in oncology. In addition, mRNA platforms are very scalable and economical in the long term, enabling drug companies to vary production levels quickly without having to replace infrastructure. The success of mRNA vaccines has proved the commercial potential and effectiveness of this method, which has led to increased investment, collaborations, and R&D efforts worldwide. This versatility is still drawing interest from researchers, governments, and investors.
One of the major constraints to the broad application of mRNA therapeutics is the need for rigorous cold chain logistics and stability issues. mRNA molecules are naturally unstable and extremely sensitive to degradation, requiring ultra-cold storage temperatures to preserve their activity during transportation and storage. For instance, certain mRNA-based COVID-19 vaccines needed to be stored at temperatures as low as -70°C, creating logistical challenges in low-resource environments and restricting global distribution. Such storage needs raise the total cost and complexity of supply chains, especially in rural and under-served areas where infrastructure is poor. Additionally, even minimal changes in temperature will undermine the stability of the therapeutic, leading to lower efficacy or greater risk of side effects. While continuous research aims to increase the thermal stability of mRNA formulations, existing limitations are currently a major bottleneck towards universal accessibility and large-scale global distribution. Overcoming this restraint is key to the long-term success of the market.
The market for mRNA therapeutics is of vast potential for growth beyond the infectious diseases to other fields like oncology, rare genetic diseases, and autoimmune diseases. The versatility of mRNA platforms enables rapid design of tailored therapies, particularly in cancer, where therapies can be designed to target specific tumor antigens. Firms already have mRNA-based cancer vaccines being tested in the clinic, hoping to get the immune system to target and destroy cancer cells. Also, mRNA can be used to replace a defective or absent protein in inherited disorders, representing an alternative with fewer risks compared to gene therapy. As understanding about disease-related biomarkers and cell mechanisms deepens, mRNA becomes a robust platform for precision medicine. Regulatory bodies have been receptive to the approval of innovative treatments, further driving R&D in such segments. As technology continues to enhance delivery methods and stability, the addressable market for mRNA treatments is poised to expand considerably in the years ahead.
One of the leading trends influencing the market is the increase in strategic collaborations and investments to speed up innovation and commercialization. Biotech firms, pharmaceutical titans, and research institutions are aggressively forging partnerships to consolidate knowledge in mRNA production, delivery technology, and disease-specific targeting. The success of mRNA vaccines not only confirmed the science behind the technology but also drew billions worth of investment from venture capitalists, governments, and health agencies. For instance, BioNTech and Moderna have made significant public and private investments to strengthen their pipelines outside of COVID-19. Such alliances are not only being made in the field of vaccine research but also in therapeutic drugs such as cardiovascular diseases, metabolic diseases, and rare diseases. Furthermore, alliances with contract development and manufacturing organizations (CDMOs) are also simplifying production and distribution processes. This expanding universe of partnerships is driving accelerated innovation and scaling, making mRNA a foundational pillar of future therapeutics in a variety of domains.
Largest Share of the Region:
North America, especially the United States, is the fastest-growing region in the market due to huge investment in research and development, a strong healthcare infrastructure, and supportive government policies. The success of mRNA-based COVID-19 vaccines, including those produced by Moderna and Pfizer-BioNTech, has made the region a global leader in the use and commercialization of mRNA therapeutics. The U.S. government's investment programs, such as Operation Warp Speed, greatly sped up vaccine development, proving the efficacy and promise of mRNA technologies in addressing infectious and non-infectious diseases. In addition, North America's sophisticated biopharmaceutical industry, including top players such as Moderna, Pfizer, and biotech companies, continues to draw large venture capital investments. This development is also driven by increasing emphasis on personalized medicine and expedited regulatory routes offered by agencies such as the FDA.
Fastest Growing/ Emerging Region:
The Asia-Pacific (APAC) region is becoming a major force in the market for mRNA therapeutics, with China, Japan, and India at the forefront. The region's increasing healthcare spending, prevalence of chronic diseases, and rising government investment in biotechnology and healthcare infrastructure are fuelling the rapid growth of the market. Specifically, China is heavily investing in mRNA research and has initiated clinical trials for indigenous mRNA vaccines, further driving market growth. Japan's robust pharmaceutical and biotechnology industries, combined with its emphasis on healthcare solutions for the aging population, provide a rich ground for mRNA therapeutics. In addition, growth in biomanufacturing capacities and favourable regulatory conditions in nations such as Singapore are supporting mRNA vaccine manufacturing and therapeutic development in the region. Opportunities exist in the APAC market for both new entrants and established players, hence providing a potential region for market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 13,874.3 million |
|
Market Size in 2031 |
US$ 40,898.5 million |
|
Market CAGR |
16.7% |
|
By Product Type |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
PBI Analysts anticipate that the market is poised for robust growth, driven by technological advancements and expanding applications beyond infectious diseases. PBI Analysts highlight the transformative impact of mRNA vaccines during the COVID-19 pandemic as a key catalyst, demonstrating the platform’s rapid development and high efficacy. Despite challenges related to delivery and stability, ongoing innovations in lipid nanoparticle technology and regulatory support are expected to overcome these barriers. The market shows promising potential in oncology, genetic disorders, and personalized medicine, attracting significant investments from pharmaceutical and biotech companies. Overall, the mRNA therapeutics landscape is evolving rapidly, offering substantial opportunities for innovation and commercial expansion in the coming decade.
Download Free Sample Report
MRNA therapeutics market size was valued at US$ 13,874.3 million in 2024 and is projected to reach US$ 40,898.5 million by 2031 at a CAGR of 16.7%.
mRNA therapeutics are treatments that use messenger RNA molecules to instruct cells to produce specific proteins, helping prevent or treat diseases such as infections, cancer, and genetic disorders.
mRNA vaccines deliver synthetic mRNA into the body, which instructs cells to produce a protein similar to a virus or pathogen, triggering an immune response without causing disease.
Key challenges include the stability of mRNA molecules, the need for ultra-cold storage and transport, and efficient delivery methods to target cells safely and effectively.
North America currently leads the market due to strong R&D investment, with Asia-Pacific emerging rapidly thanks to increasing healthcare infrastructure and government support.
Market research is segmented based on product type, application, end user and region.
| 1.Executive Summary |
| 2.Global Mrna Therapeutics Market Introduction |
| 2.1.Global Mrna Therapeutics Market - Taxonomy |
| 2.2.Global Mrna Therapeutics Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Application |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Mrna Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Mrna Therapeutics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Mrna Therapeutics Market By Product Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. mRNA Vaccines |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. mRNA Therapeutics |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Mrna Therapeutics Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Infectious Diseases |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Oncology |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Genetic Disorders |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Autoimmune Diseases |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Cardiovascular Diseases |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Mrna Therapeutics Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Pharmaceutical & Biotechnology Companies |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Academic & Research Institutes |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Contract Research Organizations (CROs) |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Hospitals & Clinics |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Mrna Therapeutics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Mrna Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Product Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.mRNA Vaccines |
| 9.1.2.mRNA Therapeutics |
| 9.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Infectious Diseases |
| 9.2.2.Oncology |
| 9.2.3.Genetic Disorders |
| 9.2.4.Autoimmune Diseases |
| 9.2.5.Cardiovascular Diseases |
| 9.2.6.Others |
| 9.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Pharmaceutical & Biotechnology Companies |
| 9.3.2.Academic & Research Institutes |
| 9.3.3.Contract Research Organizations (CROs) |
| 9.3.4.Hospitals & Clinics |
| 9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Mrna Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.mRNA Vaccines |
| 10.1.2.mRNA Therapeutics |
| 10.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Infectious Diseases |
| 10.2.2.Oncology |
| 10.2.3.Genetic Disorders |
| 10.2.4.Autoimmune Diseases |
| 10.2.5.Cardiovascular Diseases |
| 10.2.6.Others |
| 10.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Pharmaceutical & Biotechnology Companies |
| 10.3.2.Academic & Research Institutes |
| 10.3.3.Contract Research Organizations (CROs) |
| 10.3.4.Hospitals & Clinics |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Mrna Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.mRNA Vaccines |
| 11.1.2.mRNA Therapeutics |
| 11.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Infectious Diseases |
| 11.2.2.Oncology |
| 11.2.3.Genetic Disorders |
| 11.2.4.Autoimmune Diseases |
| 11.2.5.Cardiovascular Diseases |
| 11.2.6.Others |
| 11.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Pharmaceutical & Biotechnology Companies |
| 11.3.2.Academic & Research Institutes |
| 11.3.3.Contract Research Organizations (CROs) |
| 11.3.4.Hospitals & Clinics |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Mrna Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.mRNA Vaccines |
| 12.1.2.mRNA Therapeutics |
| 12.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Infectious Diseases |
| 12.2.2.Oncology |
| 12.2.3.Genetic Disorders |
| 12.2.4.Autoimmune Diseases |
| 12.2.5.Cardiovascular Diseases |
| 12.2.6.Others |
| 12.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Pharmaceutical & Biotechnology Companies |
| 12.3.2.Academic & Research Institutes |
| 12.3.3.Contract Research Organizations (CROs) |
| 12.3.4.Hospitals & Clinics |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Mrna Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.mRNA Vaccines |
| 13.1.2.mRNA Therapeutics |
| 13.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Infectious Diseases |
| 13.2.2.Oncology |
| 13.2.3.Genetic Disorders |
| 13.2.4.Autoimmune Diseases |
| 13.2.5.Cardiovascular Diseases |
| 13.2.6.Others |
| 13.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Pharmaceutical & Biotechnology Companies |
| 13.3.2.Academic & Research Institutes |
| 13.3.3.Contract Research Organizations (CROs) |
| 13.3.4.Hospitals & Clinics |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Moderna, Inc. |
| 14.2.2.BioNTech SE |
| 14.2.3.CureVac N.V. |
| 14.2.4.Arcturus Therapeutics |
| 14.2.5.Translate Bio, Inc. |
| 14.2.6.GSK plc. |
| 14.2.7.Argos Therapeutics Inc. |
| 14.2.8.Sangamo Therapeutics, Inc. |
| 14.2.9.Pfizer Inc. |
| 14.2.10.AstraZeneca plc. |
| 14.2.11.Sanofi |
| 14.2.12.CRISPR Therapeutics AG |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
